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Glucocorticoids and adipose tissue function 
Acute hypercortisolemia exerts depot-specific effects on abdominal and 
femoral adipose tissue function 
Konstantinos N. Manolopoulos1,2, Michael W. O’Reilly1,2, Iwona J. Bujalska1, Jeremy W. 
Tomlinson3 *, Wiebke Arlt1,2,4 * 
1Institute of Metabolism and Systems Research (IMSR), University of Birmingham, B15 2TT, UK 
2Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TH, UK 
3Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre University 
of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK 
4National Insittute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit, University Hospitals 
Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK 
Received 03 November 2016. Accepted 13 February 2017. 
*These authors contributed equally. 
Context: Glucocorticoids have pleiotropic metabolic functions and acute glucocorticoid excess 
affects fatty acid metabolism, increasing systemic lipolysis. Whether glucocorticoids exert 
adipose tissue depot-specific effects remains unclear. 
Objective: In vivo assessment of femoral and abdominal adipose tissue responses to acute 
glucocorticoid administration. 
Design and outcome measures: Nine healthy male volunteers studied on two occasions, 
following a hydrocortisone infusion (0.2 mg.kg-1.min-1 for 14 hours) and saline, respectively, 
given in randomized double-blind order. Subjects were studied in the fasting state and following 
a 75g glucose drink with in vivo assessment of femoral adipose tissue blood flow (ATBF) using 
radioactive Xenon washout, and lipolysis and glucose uptake using the arterio-venous difference 
technique. In a separate study (same infusion design), 8 further healthy male subjects underwent 
assessment of fasting abdominal ATBF and lipolysis only. Lipolysis was assessed as the net 
release of non-esterified fatty acids (NEFA) from femoral and abdominal subcutaneous adipose 
tissue. 
Results: Acute hypercortisolemia significantly increased basal and postprandial ATBF in 
femoral adipose tissue, but femoral net NEFA release did not change. In abdominal adipose 
tissue, hypercortisolemia induced significant increases in basal ATBF and NEFA release. 
Conclusions: Acute hypercortisolemia induces differential lipolysis and ATBF responses in 
abdominal and femoral adipose tissue, suggesting depot-specific glucocorticoid effects. 
Abdominal, but not femoral, adipose tissue contributes to the hypercortisolemia-induced 
systemic NEFA increase, with likely contributions from other adipose tissue sources and 
intravascular triglyceride hydrolysis. 
Acute experimental hypercortisolemia induces differential metabolic responses in abdominal and femoral 
adipose tissue in vivo, suggesting depot-specific glucocorticoid effects in humans. 
Introduction 
Glucocorticoids (GC) are important pleiotropic hormones that exert anabolic effects during 
physiological conditions, but also play a pivotal role in tissue catabolism when acutely elevated 
as part of an acute stress response (1). In contrast, chronic pathophysiological GC excess in 
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Cushing’s syndrome is characterised by a distinctive centripetal fat mass redistribution and in 
particular visceral fat mass accumulation and is associated with increased morbidity and 
mortality (2,3). Body fat mass distribution is an important determinant of health and abdominal 
fat mass accumulation represents a major risk factor for cardiovascular disease (4). In contrast, a 
larger thigh subcutaneous fat mass is independently associated with favorable cardiovascular and 
metabolic profiles (5), and relative scarcity of femoral fat may have important implications for 
cardiometabolic health (6,7). Femoral adipose tissue mass is determined by the balance between 
fatty acid uptake and their release, lipolysis, whereby the latter is regulated in vivo in a depot-
specific manner via selective adrenoceptor action (8). 
Acute hypercortisolemia results in an increase of whole body lipolysis, i.e. the release of 
non-esterified fatty acids (NEFA) from adipose tissue, but the exact effects of GC on depot-
specific lipolysis remain unclear (9). Murine in vitro models have yielded conflicting results, 
with only some reporting induction of lipolysis by GC in a dose-dependent manner (reviewed in 
(1)). In intact human adipocytes isolated from the abdominal subcutaneous depot, cortisol 
treatment resulted in inhibition of basal and β-adrenergic-mediated lipolysis (10). In contrast, 
lipolysis appeared unaffected by the synthetic glucocorticoid dexamethasone (11,12). Early in 
vivo studies also showed that GC inhibit sympathetic activity and adrenoceptor function in 
humans (13,14), suggesting this could affect lipolytic responses. However, femoral lipolysis, 
determined as glycerol release using the microdialysis technique, has been found to either 
increase (15) or remain unchanged (16) in experimental GC excess. 
The aim of our study was to study lipolysis in response to acute GC excess, using an 
integrative in vivo physiology approach. In particular, we sought to investigate the depot-specific 
contribution of femoral adipose tissue to whole body lipolysis during hypercortisolemia. Based 
on previous studies (17,18), we hypothesized that acute elevation of cortisol concentrations 
would affect femoral adipose tissue blood flow (ATBF) and NEFA release in line with an acute 
catabolic response. Furthermore, we studied femoral adipose tissue postprandial glucose uptake, 
as well as, in a separate study, abdominal adipose tissue fasting ATBF and NEFA release as 
markers of depot-specific adipose tissue function in vivo. 
Methods 
Subjects 
Healthy male individuals with no medical condition and not on any drug therapy were recruited 
using print and electronic advertising. All subjects underwent a medical evaluation during the 
screening visit to ensure they were healthy, and had normal liver and kidney function parameters 
as well as normal blood counts. No subject had any significant past medical history, smoked 
tobacco or took any regular medications that could affect the study’s outcome measures. All 
parts of this study were conducted at the National Institute for Health Research/Wellcome Trust 
Clinical Research Facility (CRF) of the University of Birmingham/Queen Elizabeth Hospital 
Birmingham. The study was approved by Solihull National Health System Research Ethics 
Committee (12/WM/0327), and all subjects gave informed consent in writing prior to 
participation. 
Study design 
Anthropometric measurements.  
Measurements were taken during the screening visit. Waist circumference was measured midway 
between the lower margin of the last palpable rib and the top of the iliac crest, and hip 
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circumference at the level of the greater trochanters. Total and regional fat masses (including 
estimated visceral fat mass) were measured by dual-energy x-ray absorptiometry (DXA) (19). 
Blood pressure and heart rate were measured using a standard oscillometric blood pressure 
monitor with an upper arm cuff. 
Study visits.  
For each of the two study visits, subjects were admitted to the CRF at 17:00h, and a cannula for 
infusion purposes was inserted into an antecubital fossa vein (Figure 1A). At 18:00h they were 
served a standardized calorie-controlled meal (vegetable lasagne; energy 2634 kJ, total 
nutritional content: 14.4 g fat, 93 g carbohydrates, 25.2 g protein, 11.4 g fibre), and then fasted 
until study completion the next day. At 19:00h a constant infusion of either hydrocortisone (0.2 
mg.kg-1.h-1, total dose infused equivalent to doses commonly used in the setting of adrenal 
insufficiency and acute illness) or saline (control study visit) was started and continued over 14 
hours until study completion the next day. The two study days were separated by at least two 
weeks, and hydrocortisone and saline infusions were administered in a double-blind, randomized 
fashion. At 22:00h lights were switched off for night rest. At 08:00h the next morning catheters 
were placed into veins draining femoral (study 1) or abdominal (study 2) subcutaneous adipose 
tissue (see below) (20,21). A further cannula was inserted either retrogradely into a vein of the 
dorsal hand, which was then placed into a hot box at 60°C for obtaining arterialized blood 
samples (study 1), or in a radial artery (study 2). For the purposes of ATBF measurement, 133Xe 
was injected into femoral (study 1) or abdominal (study 2) subcutaneous adipose tissue (22), and 
scintillation was measured continuously with customized Cesium detectors (GMS411 system, 
John Caunt Scientific, Bury, UK). After this, study participants were left to relax for 45 min in 
order to allow equilibration of 133Xe. Before the start of blood sampling, blood pressure and heart 
rate were measured. After study completion, all catheters were removed and the subjects were 
given a full meal. 
Region-specific blood sampling.  
In nine participants (study 1), a venous catheter was placed into the femoral saphenous vein and, 
following blood sampling at regular intervals for two hours (fasting phase), a standardized 75g 
glucose drink was given at 120 min. Blood sampling continued for another 2 hours. In a separate 
study (study 2) with the same infusion design and duration as outlined above, we studied 
abdominal ATBF and NEFA release in eight participants by taking samples from a superficial 
epigastric vein, whereby sampling was performed under fasting conditions only. In both studies, 
all venous and arterial/arterialized samples were taken simultaneously at specified times (arterio-
venous difference technique) (20,23). 
Analytical methods 
Blood samples were drawn into heparinized syringes, and plasma was prepared rapidly at 4°C 
and immediately frozen at -80°C before analysis. Plasma glucose, NEFA and glycerol 
concentrations were measured enzymatically using commercially available kits on an ILAB600 
or ILAB650 clinical analyser (Instrumentation Laboratory UK, Warrington, UK); cortisol was 
measured by a colorimetric assay (R&D Systems, Abingdon, UK); insulin and C-peptide were 
measured by ELISA (Invitron, Monmouth, UK) in an accredited reference laboratory (Diabetes 
Research Unit, Swansea University). IL-6 was measured by ELISA (Thermo Fisher Scientific, 
Loughborough, UK). 
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Calculations and statistics 
Indices of pancreatic β-cell function and insulin resistance were calculated according to the 
updated homeostatic model assessment (HOMA) method using the computer model (24), 
whereby the calculations are given in the Supplemental Methods section. The mean of three 
consecutive plasma glucose and insulin fasting measurements (time points 0-30 min) was used 
for HOMA calculations. Metabolite uptake and release across abdominal and femoral adipose 
tissue were calculated with the arterio-venous difference technique (8). For NEFA and glycerol 
release, the veno-arterial concentration difference was multiplied by ATBF for each of the 
abdominal and femoral adipose tissue depots respectively. For glucose uptake, the arterio-venous 
concentration difference was multiplied by ATBF. A detailed description of all calculations is 
given in the Supplemental Methods section. For study 1, comparisons between control and 
hypercortisolemia were performed for each time point (pairwise comparisons) or by comparing 
areas under the curve (AUC). AUC was also used for comparisons between fasting and 
postprandial states. Area under the curve was calculated using the trapezoid rule and is presented 
as a time-averaged value (AUC divided by the relevant time period). For study 2, the mean of 
three fasting measurements (time points 0-30 min) was used for all calculations and 
comparisons. To calculate ratios and re-esterification rates in both studies 1 and 2, the mean of 
three measurements (time points 0-30 min) was used to calculate fasting data, while for femoral 
adipose tissue the mean of time points 200-240 min was used for postprandial calculations. Data 
distribution was tested for normality with the Shapiro-Wilk test, and parametric or non-
parametric tests were used as indicated. Data were analyzed using IBM Statistics for Windows 
v21 and GraphPad Prism for Windows v6.05. A p<0.05 was considered significant. All data are 
presented as mean ± SEM, unless otherwise stated. 
Results 
Baseline anthropometric and metabolic characteristics of subjects are shown in Table 1. 
Hydrocortisone infusion did result in a mild increase in heart rate (p=0.033 for study 1, p=0.022 
for study 2, compared to control, paired T-test), but did not affect blood pressure. 
Hydrocortisone infusion leads to increased systemic NEFA and peripheral insulin resistance 
In study 1 (femoral adipose tissue depot), hydrocortisone infusion resulted in a significant 
increase in cortisol concentrations (AUC 0-240 min saline vs hydrocortisone, p=0.008, 
Wilcoxon) (Figure 1B). Hypercortisolemia had significant effects on plasma NEFA and glucose 
concentrations. Compared to control, plasma NEFA increased 1.6-fold in the fasting state (AUC 
0-120 min saline vs hydrocortisone, p=0.008, Wilcoxon). Following glucose ingestion, plasma 
NEFA concentrations became suppressed under control conditions (AUC 0-120 min vs AUC 
120-240 min, p=0.008, Wilcoxon). In hypercortisolemia, plasma NEFA concentrations also 
became suppressed following glucose ingestion (AUC 0-120 min vs AUC 120-240 min, 
p=0.008, Wilcoxon).  Compared to control, postprandial plasma NEFA concentrations remained 
higher during hydrocortisone infusion (AUC 120-240 min saline vs hydrocortisone, p=0.008, 
Wilcoxon) (Figure 1C). In response to hydrocortisone infusion, plasma glucose increased 1.3-
fold both in the fasting (AUC 0-120 min saline vs hydrocortisone, p=0.008, Wilcoxon) and the 
postprandial state (AUC 120-240 min saline vs hydrocortisone, p=0.008, Wilcoxon) compared to 
control study visits (Figure 1D). 
Overall plasma insulin concentrations increased during hydrocortisone infusion (AUC 0-240 
min saline vs hydrocortisone, p=0.018, Wilcoxon) (Figure 2A). This was more pronounced for 
fasting, i.e. basal, insulin secretion (individual time points 0-120 min saline vs hydrocortisone, 
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p<0.001 for infusion type, ANOVA), whereas glucose-stimulated secretion, both in terms of 
response time and magnitude, appeared less affected by hydrocortisone (individual time points 
120-240 min saline vs hydrocortisone, p=0.051 for infusion type, p=0.077 infusion type x time, 
ANOVA). Plasma C-peptide secretion responses to hydrocortisone infusion mirrored that of 
insulin, with a significant fasting increase compared to control (individual time points 0-120 min 
saline vs hydrocortisone, p<0.001 for infusion type, ANOVA). Similarly to insulin, this increase 
was not seen in the postprandial phase (individual time points 120-240 min saline vs 
hydrocortisone, p=0.441 for infusion type, p=0.093 infusion type x time, ANOVA) (Figure 2B). 
Accordingly, pancreatic β-cell function (HOMA %B) did not change significantly during 
hydrocortisone infusion compared to control (saline vs hydrocortisone, p=0.374, Wilcoxon), but 
insulin sensitivity (HOMA %S) did decrease dramatically (saline vs hydrocortisone, p=0.008, 
Wilcoxon) (Figure 2C). In line with this, insulin resistance (HOMA IR) increased during 
hydrocortisone infusion (saline vs hydrocortisone, p=0.012, Wilcoxon) (Figure 2D). 
Fasting and postprandial femoral ATBF increases during hypercortisolemia 
During control conditions, femoral ATBF was stable in the fasting phase and following glucose 
ingestion (individual time points 0-240 min saline, p=0.155 prandial state x time, ANOVA) 
(Figure 3A). Hydrocortisone infusion induced a steady increase in femoral ATBF during the 
fasting phase (individual time points 0-120 min saline vs hydrocortisone, p=0.009 infusion type x 
time, ANOVA). Following glucose ingestion there was a further marked increase in femoral 
ATBF compared to control (AUC 120-240 min saline vs hydrocortisone, p=0.011, Wilcoxon). In 
addition, hydrocortisone induced a larger ATBF-change in the fasting to postprandial state 
transition (∆ AUC fasting/postprandial saline vs hydrocortisone, p=0.024, Wilcoxon) (Figure 
3B). 
Femoral lipolysis and glucose uptake remain unaffected by hypercortisolemia 
Fasting femoral NEFA release rate was 671±232 nmol.min-1.100g tissue-1 (AUC 0-120 min) 
under control conditions (Figure 3C). Expectedly, following glucose ingestion lipolysis was 
inhibited (AUC 0-120 min vs 120-240 min, p=0.021, Wilcoxon). During hydrocortisone 
infusion, fasting and postprandial NEFA release rate were similar to control conditions 
(individual time points 0-120 min, p=0.285, and individual time points 120-240 min, p=0.447, 
infusion type x time respectively, ANOVA saline vs hydrocortisone) (Figure 3C). There was no 
difference in the degree of lipolysis suppression by glucose (∆ AUC fasting/postprandial for 
saline vs hydrocortisone, p=0.824, Wilcoxon) (Figure 3D). Regional glycerol release, a further 
marker of lipolysis, essentially mirrored NEFA release (Figure 3E).  
During control conditions, the fasting femoral adipose tissue glucose uptake rate was 0.2±0.1 
µmol.min-1.100g tissue-1 (AUC 0-120 min) (Figure 3F). Following glucose, uptake peaked to 
2.3±0.7 µmol.min-1.100g tissue-1 at 160 min, but the overall postprandial AUC remained 
unchanged to fasting (AUC 0-120 min vs AUC 120-240 min, p=0.102, Wilcoxon). The fasting 
and postprandial glucose uptake responses remained virtually the same during both control and 
hydrocortisone infusion states (AUC 0-240 min saline vs hydrocortisone, p=0.926 depot x 
prandial state x infusion type, ANOVA). 
Acute hypercortisolemia increases fasting abdominal ATBF and lipolytic rate 
In study 2 (abdominal adipose tissue depot), we compared fasting abdominal ATBF and lipolysis 
in the presence of hypercortisolemia to control conditions using the same infusion regime, which 
again resulted in significant increases in plasma cortisol (Figure 4A) and NEFA concentrations 
(Figure 4B). Given that the study was carried out in the fasting state only, we did not measure 
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abdominal adipose tissue glucose uptake. Hypercortisolemia increased fasting ATBF (mean 0-30 
min saline vs hypercortisolemia, p=0.039, paired T-test) (Figure 4C). Abdominal fasting net 
NEFA release also increased compared to control (mean 0-30 min saline 1446±334 nmol.min-
1
.100g tissue-1 vs hypercortisolemia 2293±541 nmol.min-1.100g tissue-1, p=0.031, paired T-test) 
(Figure 4D), as did abdominal fasting net glycerol release (mean 0-30 min saline vs 
hypercortisolemia, p=0.021, paired T-test) (Figure 4E).  
NEFA handling in femoral and abdominal adipose tissue 
Because of the increased systemic NEFA concentrations and the marked increases in ATBF 
observed during hypercortisolemia, we sought to calculate markers of NEFA handling in each 
depot that are independent of ATBF. Thus, as a marker of local lipolysis at the adipocyte level, 
we calculated the fasting veno-arterial NEFA ratio. In femoral adipose tissue, the ratio decreased 
from 1.8±0.2 under control conditions to 1.3±0.1 in hypercortisolemia (mean 0-30 min saline vs 
hydrocortisone, p=0.035, Wilcoxon). Similarly, in abdominal adipose tissue it decreased from 
2.3±0.2 to 1.7±0.1 (mean 0-30 min, p=0.035, Wilcoxon). 
Systemic and regional adipose tissue IL-6 production 
Cortisol exerts a wide range of non-metabolic effects and we measured IL-6 production as an 
inflammatory marker in response to the hydrocortisone infusion (Suppl. Figure 1). Systemic 
fasting plasma IL-6 concentrations did not change significantly between control and 
hypercortisolemia conditions (time point 0 min, 11.7±3.6 pg/mL vs. 12.7±6.9 pg/mL, p=0.798). 
Abdominal adipose tissue appeared to be a net producer of IL-6 (release control 12.6±5.6 pg.mL-
1
.100g tissue-1; hypercortisolemia 19.7±9.7 pg.mL-1.100g tissue-1); however this did not reach 
statistical significance (control p=0.109; hypercortisolemia p=0.087, one-sample T-test 
compared to zero). Femoral adipose tissue IL-6 release was statistically not different from zero 
(femoral IL-6 release control control 1.14±0.56 pg.mL-1.100g tissue-1; hypercortisolemia 
-0.28±2.86 pg.mL-1.100g tissue-1; p=0.077 and p=0.925, respectively, one-sample T-test 
compared to zero). 
Discussion 
Glucocorticoids have important metabolic functions that are tissue-specific and vary depending 
on the length of exposure (1). In relation to their effect on in vivo fatty acid metabolism, there is 
general agreement that hypercortisolemia increases plasma NEFA concentrations (15,17,25,26). 
However, the exact source of NEFA is still debated, with some studies reporting an increase of 
abdominal lipolysis (15,27), while others found a reduction (17). Given the previously reported 
differences in the depot-specific regulation of lipolysis (8), we studied the effects of acute 
hypercortisolemia on the femoral and abdominal adipose tissue depot using an integrative in vivo 
physiology approach. We found that during hypercortisolemia abdominal net NEFA output 
increased, while femoral NEFA release remained stable despite a striking increase in femoral 
ATBF. We describe potential effects of the increased ATBF on local NEFA handling during 
hypercortisolemia, and suggest that other depots, e.g. visceral adipose tissue, may play a role in 
the systemic NEFA concentrations increase, in addition to the contribution of abdominal NEFA 
release. 
However, it remains unresolved which adipose tissue depots contribute to the systemic 
increases in plasma NEFA during hypercortisolemia, and whether differential contribution of 
specific adipose tissue depots gives rise to phenotypic fat mass distribution changes observed in 
chronic GC excess. Similar to previous studies (15,17,25,26), we found a marked increase of 
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systemic NEFA concentrations in the fasting state during GC infusion. Using isotope tracers, it 
has been shown that palmitate and glycerol rates of appearance increase with hydrocortisone, 
suggesting induction of lipolysis at the systemic level (15,17). Subcutaneous adipose tissue is the 
major source of NEFA, driven by the activity of adipocyte-specific lipases, most notably adipose 
tissue triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) (28). The NEFA rate of 
appearance in the systemic circulation is determined by ATBF and the net lipolytic rate of the 
individual adipose tissue depots (20,29). We studied these parameters in order to measure the 
individual contribution of the femoral and abdominal depot to the increased systemic NEFA 
concentrations in hypercortisolemia, hypothesizing that femoral adipose tissue is a net 
contributor. 
We found a steady rise of femoral ATBF during fasting conditions during GC infusion, with 
a further major increase in the postprandial phase. This is in stark contrast to the previously 
described picture of a mostly unresponsive femoral ATBF (8). Contrary to our hypothesis, we 
found no differences in femoral lipolytic rate during hydrocortisone infusion. In fact, our data 
suggest a strong inhibition of lipolysis at the actual adipocyte level, since the net femoral 
lipolytic rate did not change after GC infusion, despite the marked local ATBF increase. We 
found a moderate increase of basal abdominal ATBF and a small net increase in the fasting 
abdominal NEFA release during hypercortisolemia. 
We did not measure triglyceride concentrations since we were not expecting any changes due 
to the nature of the experimental meal stimulus (pure glucose) and therefore could not calculate 
the exact transcapillary flux of fatty acids (30). Hence, the exact effects of GC excess on 
postprandial fatty acid trafficking, would need to be studied in future experiments ideally 
involving a lipid-containing meal.  
ATBF is an important determinant of adipose tissue function as it determines the influx and 
efflux of metabolites, systemic hormones and adipokines (31). Basal ATBF is determined largely 
by nitric oxide, while the postprandial increase is mediated by β-adrenergic stimulation (32). 
Femoral ATBF is much less responsive to adrenergic stimulation due to prevailing inhibitory 
α2-adrenoceptor activity, underlining the concept of a depot-specific regulation (8). Vascular 
smooth muscle cell tone and endothelial nitric oxide synthesis are known to be affected by GC 
(reviewed in (33)). Interestingly, while GCs inhibit endothelial nitric oxide synthase, they also 
inhibit sympathetic nerve outflow in humans (13,14). In line with the latter, studies in humans 
indicate that resting systemic catecholamine rate of appearance does not change during 
hydrocortisone infusion and effects are mediated at the level of end-organ responsiveness (34). 
However, GC-mediated inhibition of the prevailing α2-adrenoceptor signalling in femoral 
adipose tissue could be a possible mechanism for the depot-specific effect on femoral ATBF 
observed in our studies. 
In our studies of healthy volunteers, hydrocortisone infusion resulted in a significant plasma 
cortisol increase with abolition of the diurnal cortisol variation. Hypercortisolemia is known to 
induce insulin resistance (35) by affecting post-receptor insulin signalling and decreasing 
glucose clearance (36,37). Our systemic metabolite data suggest that we were able to replicate 
the effects of GC excess, reflected by our findings of increased basal glucose and insulin as well 
as increased postprandial glucose concentrations. C-peptide secretion was preserved during 
hypercortisolemia, suggesting maintained pancreatic β-cell function. In line with this, HOMA 
indices showed an increase in insulin resistance with unaltered beta cell function. Taking into 
account the high HOMA insulin sensitivity values found during control conditions, these data 
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suggest that our study population consisted of very insulin sensitive individuals that were 
rendered insulin resistant by the hydrocortisone infusion. 
Interestingly, previous findings suggest GC effects on insulin sensitivity to be tissue specific, 
whereby they may induce insulin resistance in muscle, but increase insulin sensitivity in 
subcutaneous adipose tissue in vivo (26). Muscle is the main site of postprandial glucose uptake, 
while adipose tissue accounts only for a small proportion of glucose clearance (38). We found 
that adipose tissue-specific glucose uptake rates were not affected by GC-induced whole body 
insulin resistance, which supports an adipose tissue-specific insulin sensitising GC effect. 
Furthermore, insulin is the major inhibitor of adipose tissue lipolysis (28). In our study, glucose-
mediated suppression of lipolysis was not affected by hydrocortisone, underlining the exquisite 
ability of insulin to maximally suppress HSL activity, and providing further support that GC do 
not induce adipose tissue insulin resistance (26). 
In order to evaluate non-metabolic effects of the induced hypercortisolemia, we measured IL-
6 concentrations as one of the main inflammatory cytokines (39). Plasma concentrations of IL-6 
increase as part of the acute inflammatory response pathway and acute hydrocortisone 
administrations is known to reduce IL-6 concentrations, although it appears that this effect only 
becomes apparent after a few days (40). In line with this, and because our study participants were 
healthy volunteers without any pathophysiological elevations in IL-6 concentrations, we did not 
see any effects of hydrocortisone infusion on systemic IL-6 concentrations. Previously it has 
been shown that abdominal adipose tissue is a net producer of IL-6, while femoral adipose tissue 
is not (41). Our results appear to be in line with this, although they did not reach statistical 
significance, most likely due to the small sample size. 
A particular strength of our study is the integrative in vivo physiology approach chosen, 
utilizing arterio-venous differences and ATBF measurements for the assessment of NEFA 
release, the direct product of lipolysis, in response to GC excess under near-normal conditions. 
Most previous studies investigating adipose tissue depot-specific GC effects on lipolysis 
employed the microdialysis technique, which relies on the measurement of interstitial glycerol 
concentrations as an indirect index of lipolysis (42), with only a few studies including femoral 
adipose tissue responses to date (15,16,27). Djurhuus et al. found an increase in abdominal and 
femoral adipose tissue interstitial glycerol following short-term (6h) hydrocortisone infusion 
(15,27). When assessing metabolite fluxes, it is important to take into consideration depot-
specific changes in blood flow. We showed that the marked femoral-specific ATBF effect in 
response to hypercortisolemia was augmented in the postprandial phase, mostly in response to 
insulin. While insulin does not exert direct ATBF effects, it is known to be in important mediator 
(43), and in contrast to previous studies using acute GC excess as an experimental approach 
(15,27), we saw a small but significant rise in basal plasma insulin concentrations. In previous 
studies, femoral ATBF was not measured, but instead abdominal ATBF was used as a basis for 
calculating femoral interstitial glycerol release (15,16,27). In these studies, abdominal ATBF did 
not change in response to hypercortisolemia. In view of the previously unknown marked 
femoral-specific ATBF effects described here, it is possible that previous microdialysis studies 
overestimated femoral glycerol appearance. Our abdominal depot findings are in contrast to 
previous results from the only study using the same experimental approach as here, showing a 
significant decrease in abdominal NEFA efflux during hydrocortisone infusion (17). This could 
be due to the slightly higher plasma cortisol concentrations achieved in our study, resulting in an 
overall increased systemic fatty acid turnover, or other factors intrinsic to our study population 
such as differences in local 11β-HSD1 activity or ATBF responses. 
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Our study has some limitations by design, including the small size of our sample and the fact 
that conclusions can be drawn only about men. The hydrocortisone infusion was calculated to 
provide around 300mg/24h, which is a dose regularly employed in clinical practice. This resulted 
in supraphysiological plasma cortisol concentrations, around double compared to those found in 
acute stress situations (e.g. sepsis) (44). To our knowledge, there are no published studies 
examining the exact dose-dependent metabolic response in acute hypercortisolemia in vivo. 
While acute dose-dependent GC effects cannot be excluded, it is generally accepted that tissue 
responses are more dependent on GR expression and local glucocorticoid activity modulation by 
the 11β-HSD enzymes, than absolute plasma concentrations (45). In support of this, our systemic 
metabolite data are comparable with studies that achieved more physiological hypercortisolemia 
(25). The acute nature of the hypercortisolemia limits the conclusions we can draw about depot-
specific lipolysis in conditions of chronic glucocorticoid excess, i.e. Cushing’s Syndrome. 
However, the finding of isolated fasting and postprandial ATBF induction in the femoral adipose 
tissue suggests an early signal of GC induced changes in this depot. Our calculations were 
performed based on the measurement of non-labelled NEFA and glycerol only, and because our 
study protocol did not include any meal containing lipids, exact modelling of depot-specific fatty 
acid trafficking, in particular triglyceride metabolism in the postprandial state, was not possible. 
Also, metabolic flux calculations are based on the assumption of steady state, however, the stark 
blood flow effects observed in our study introduced a non-steady state situation which could 
have affected our results.  Finally, a direct comparison of the depot-specific contribution to 
systemic lipolysis between femoral and abdominal adipose tissue was not feasible, because 
measurements were not paired. With this in mind, however, there appear to be clear differential 
responses between the two depots in hypercortisolemia.  
In conclusion, we have provided evidence that acute hypercortisolemia increases plasma 
NEFA and exerts selective effects on adipose tissue lipolysis and ATBF, supporting the concept 
of tissue-and depot-specific GC actions in vivo. Femoral adipose tissue does not appear to be a 
net contributor of NEFA in hypercortisolemia, but marked changes in femoral ATBF could 
herald effects on femoral fatty acid trafficking that become evident only in chronic 
hypercortisolemia. The exact source of the excess systemic NEFA in hypercortisolemia remains 
elusive, but it can be speculated that they may derive from the visceral adipose tissue depot. The 
increase in abdominal lipolysis we observed appears not sufficient to explain the marked 
increase in plasma NEFA during hydrocortisone infusion. Future studies will need to address 
whether altered subcutaneous adipose tissue depot function and to what extent visceral adipose 
tissue lipolysis contribute to the pathophysiological changes in fatty acid metabolism in chronic 
GC excess. 
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Figure 1: Study design and systemic metabolite concentrations. Healthy male volunteers 
underwent the study twice, either receiving a constant overnight hydrocortisone or saline 
infusion until the end of the study. Infusions were given in a randomized, double-blind order. A 
standard 75g glucose drink was given at 120 min (n=9, study 1). In eight further individuals 
(study 2) blood sampling across abdominal adipose tissue was performed in the fasting state 
only. Plasma cortisol (B), NEFA (C), and glucose (D) during hydrocortisone (black squares) or 
saline infusion (open circles). Hypercortisolemia increased plasma NEFA and glucose 
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concentrations. Data from study 1, n=9, *p<0.05 compared to saline for each time point, 
Wilcoxon. 
Figure 2: Pancreatic function and insulin resistance indexes (HOMA). Plasma insulin (A) 
and C-peptide concentrations (B) during hydrocortisone (HC, black squares) or saline infusion 
(S, open circles). A standard 75g glucose drink was given at 120 min. HOMA indexes of 
pancreatic β-cell function (%B) and insulin sensitivity (%S) (C), and insulin resistance index 
(IR) (D). Hypercortisolemia increased basal insulin and C-peptide concentrations and resulted in 
peripheral insulin resistance. Data from study 1, n=9, *p<0.05 compared to saline for each time 
point, Wilcoxon. 
Figure 3: Femoral adipose tissue responses. Femoral ATBF (A) during hydrocortisone (HC, 
black squares and bars) or saline infusion (S, open circles and bars). A standard 75g glucose 
drink was given at 120 min. ATBF change in the fasting to postprandial state transition (B). 
Femoral NEFA release (C) and lipolysis suppression induced by glucose ingestion (D). Femoral 
glycerol release (E) and glucose uptake (F). Hypercortisolemia markedly increased basal and 
postprandial ATBF, but did not have any effect on femoral lipolysis or postprandial femoral 
glucose uptake. Release was calculated by multiplying the veno-arterial concentration difference 
with ATBF. Uptake was calculated by multiplying the arterio-venous concentration difference 
with ATBF. Data from study 1, n=9, *p<0.05 compared to saline for each time point, Wilcoxon. 
Figure 4: Abdominal fasting adipose tissue blood flow and lipolysis. Plasma cortisol (A) and 
fasting NEFA concentrations (B) during hydrocortisone (HC, black bars) or saline infusion (S, 
white bars). Abdominal fasting ATBF (C), NEFA release (D), and glycerol release (E) during 
control and hydrocortisone infusions. Hypercortisolemia increased abdominal ATBF and NEFA 
release. Bars represent the mean of three fasting measurements (time points 0-30 min). Release 
was calculated by multiplying the veno-arterial concentration difference with ATBF. Uptake was 
calculated by multiplying the arterio-venous concentration difference with ATBF. Data from 
study 2, n=8, *p<0.05, paired T-test. 
Table 1: Baseline anthropometric and metabolic characteristics of participants.  
Characteristic Study 1 (n=9) Study 2 (n=8) p 
Age (years) 28 (19-57) 23 (19-47) 0.53 
Weight (kg) 87.3 (67.3-96.4) 80.2 (74.0-93.0) 0.37 
BMI (kg/m2) 26.5 (22.7-30.4) 24.1 (23.1-27.5) 0.13 
Waist-to-Hip Ratio 0.9 (0.76-1.03) 0.87 (0.78-0.98) 0.47 
Trunk fat mass (kg) 13.5 (5.2-19.8) 9.0 (5.9-15.2) 0.24 
Leg fat mass (kg) 6.4 (2.9-12.4) 6.1 (4.6-12.4) 0.77 
Visceral fat mass (kg) 0.7 (0.3-1.7) 0.3 (0.2-1.2) 0.16 
BP systolic (mmHg)    
Control 129±5 131±3 0.68 
Hypercortisolemia 129±6 128±3 0.91 
BP diastolic (mmHg)    
Control 74±3 70±2 0.07 
Hypercortisolemia 73±4 67±3 0.26 
Heart rate (bpm)    
Control 62±4 63±3 0.72 
Hypercortisolemia 73±5* 73±3# 1.0 
Median and range shown 
BP, blood pressure; mean±SEM shown 
*p=0.033 compared to control; #p=0.020 compared to control 
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